The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies
Abstract Introduction The efficacy of azithromycin to prevent exacerbation for non-cystic fibrosis bronchiectasis remains controversial. We conduct this meta-analysis to explore the influence of azithromycin versus placebo for the treatment of non-cystic fibrosis bronchiectasis. Methods We have sear...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-10-01
|
| Series: | Journal of Cardiothoracic Surgery |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13019-022-01882-y |
| _version_ | 1798029991781335040 |
|---|---|
| author | Kui Li Li Liu Yan Ou |
| author_facet | Kui Li Li Liu Yan Ou |
| author_sort | Kui Li |
| collection | DOAJ |
| description | Abstract Introduction The efficacy of azithromycin to prevent exacerbation for non-cystic fibrosis bronchiectasis remains controversial. We conduct this meta-analysis to explore the influence of azithromycin versus placebo for the treatment of non-cystic fibrosis bronchiectasis. Methods We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through July 2019 for randomized controlled trials (RCTs) assessing the efficacy of azithromycin versus placebo for non-cystic fibrosis bronchiectasis. This meta-analysis was performed using the random-effect model. Results Four RCTs were included in the meta-analysis. Overall, compared with control group for non-cystic-fibrosis bronchiectasis, azithromycin treatment was associated with improved free of exacerbation (odd ratios [OR] = 3.66; 95% confidence interval [CI] = 1.69–7.93; P = 0.001), reduced pulmonary exacerbations (OR = 0.27; 95% CI 0.13–0.59; P = 0.001) and number of pulmonary exacerbations (standard mean difference [SMD] = − 0.87; 95% CI − 1.21 to − 0.54; P < 0.00001), but demonstrate no obvious impact on forced expiratory volume in 1 s (FEV1), score on St George’s respiratory questionnaire, nausea or vomiting, adverse events. Conclusions Azithromycin is effective to prevent exacerbation of non-cystic fibrosis bronchiectasis. |
| first_indexed | 2024-04-11T19:34:21Z |
| format | Article |
| id | doaj.art-9ee272cbb13349018cde140a79d19f20 |
| institution | Directory Open Access Journal |
| issn | 1749-8090 |
| language | English |
| last_indexed | 2024-04-11T19:34:21Z |
| publishDate | 2022-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Cardiothoracic Surgery |
| spelling | doaj.art-9ee272cbb13349018cde140a79d19f202022-12-22T04:06:55ZengBMCJournal of Cardiothoracic Surgery1749-80902022-10-011711810.1186/s13019-022-01882-yThe efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studiesKui Li0Li Liu1Yan Ou2Department of Respiratory and Critical Care Medicine, Chongqing Bishan District People’s HospitalDepartment of Respiratory and Critical Care Medicine, Chongqing Bishan District People’s HospitalDepartment of Respiratory and Critical Care Medicine, Chongqing Bishan District People’s HospitalAbstract Introduction The efficacy of azithromycin to prevent exacerbation for non-cystic fibrosis bronchiectasis remains controversial. We conduct this meta-analysis to explore the influence of azithromycin versus placebo for the treatment of non-cystic fibrosis bronchiectasis. Methods We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through July 2019 for randomized controlled trials (RCTs) assessing the efficacy of azithromycin versus placebo for non-cystic fibrosis bronchiectasis. This meta-analysis was performed using the random-effect model. Results Four RCTs were included in the meta-analysis. Overall, compared with control group for non-cystic-fibrosis bronchiectasis, azithromycin treatment was associated with improved free of exacerbation (odd ratios [OR] = 3.66; 95% confidence interval [CI] = 1.69–7.93; P = 0.001), reduced pulmonary exacerbations (OR = 0.27; 95% CI 0.13–0.59; P = 0.001) and number of pulmonary exacerbations (standard mean difference [SMD] = − 0.87; 95% CI − 1.21 to − 0.54; P < 0.00001), but demonstrate no obvious impact on forced expiratory volume in 1 s (FEV1), score on St George’s respiratory questionnaire, nausea or vomiting, adverse events. Conclusions Azithromycin is effective to prevent exacerbation of non-cystic fibrosis bronchiectasis.https://doi.org/10.1186/s13019-022-01882-yAzithromycinNon-cystic fibrosis bronchiectasisExacerbationRandomized controlled trials |
| spellingShingle | Kui Li Li Liu Yan Ou The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies Journal of Cardiothoracic Surgery Azithromycin Non-cystic fibrosis bronchiectasis Exacerbation Randomized controlled trials |
| title | The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies |
| title_full | The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies |
| title_fullStr | The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies |
| title_full_unstemmed | The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies |
| title_short | The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies |
| title_sort | efficacy of azithromycin to prevent exacerbation of non cystic fibrosis bronchiectasis a meta analysis of randomized controlled studies |
| topic | Azithromycin Non-cystic fibrosis bronchiectasis Exacerbation Randomized controlled trials |
| url | https://doi.org/10.1186/s13019-022-01882-y |
| work_keys_str_mv | AT kuili theefficacyofazithromycintopreventexacerbationofnoncysticfibrosisbronchiectasisametaanalysisofrandomizedcontrolledstudies AT liliu theefficacyofazithromycintopreventexacerbationofnoncysticfibrosisbronchiectasisametaanalysisofrandomizedcontrolledstudies AT yanou theefficacyofazithromycintopreventexacerbationofnoncysticfibrosisbronchiectasisametaanalysisofrandomizedcontrolledstudies AT kuili efficacyofazithromycintopreventexacerbationofnoncysticfibrosisbronchiectasisametaanalysisofrandomizedcontrolledstudies AT liliu efficacyofazithromycintopreventexacerbationofnoncysticfibrosisbronchiectasisametaanalysisofrandomizedcontrolledstudies AT yanou efficacyofazithromycintopreventexacerbationofnoncysticfibrosisbronchiectasisametaanalysisofrandomizedcontrolledstudies |